ADVERTISEMENT
GSK Pharma Q4 Review: ICICI Securities Downgrades To 'Reduce' On Expensive Valuation, But Hikes Target Price
ICICI Securities downgrade GSK Pharma to Reduce on expensive valuation; raises target price to Rs 2,600 based on 38x FY27E EPS.
14 May 2025, 10:37 AM IST 
GSK Pharma's Ebitda margin touches a new high of 34% in Q4 FY25 (Photo Source: freepik)
GSK Pharma's revenue for the recently launched patented brands Nucala and Trelegy was Rs 1.0 billion–1.5 billion in FY25. Respiratory portfolio led by Nucala and Trelegy continues to gain market share, while monthly doses of Shingrix surged to a high of 10,000 in Mar’25.
